As of 2025-12-21, the EV/EBITDA ratio of Reata Pharmaceuticals Inc (RETA) is -15.37. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RETA's latest enterprise value is 5,813.45 mil USD. RETA's TTM EBITDA according to its financial statements is -378.12 mil USD. Dividing these 2 quantities gives us the above RETA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.4x - 15.3x | 11.4x |
| Forward P/E multiples | 12.9x - 15.5x | 14.6x |
| Fair Price | (146.40) - (172.74) | (147.36) |
| Upside | -184.9% - -200.2% | -185.5% |
| Date | EV/EBITDA |